International journal of psychiatry in clinical practice · 2025
Rapid treatment initiation in patients with schizophrenia: evaluation of the clinical and functional outcomes of the two-injection start regimen of aripiprazole once-monthly.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Yılmaz Yavuz, Yavuz Seda, Soğucak Suna, Çam Selim
Аннотация
OBJECTIVE: This study aims to evaluate the short-term efficacy, safety, tolerability, and side effect profile of the two-injection start (TIS) regimen of aripiprazole once-monthly long-acting injection (AOM 400 mg) in individuals diagnosed with schizophrenia.
METHODS: This retrospective study included 50 patients diagnosed with schizophrenia according to DSM-5 criteria who received the TIS regimen of AOM 400 mg. Patients were divided into two groups: those followed with AOM monotherapy (Group 1) and those receiving AOM with oral agents (Group 2). Assessments included the Positive and Negative Syndrome Scale (PANSS), Clinical Global Impression scales (CGI-S, CGI-I, CGI-SE), and the Global Assessment of Functioning (GAF). Evaluations were performed at baseline and at weeks 1, 2, and 4. Hospital stay duration and side effects were recorded.
RESULTS: Both groups showed significant reductions in hospital stay and PANSS scores, with improved GAF and CGI-I scores (p < 0.001). No serious side effects occurred, and mild effects resolved by week 4.
CONCLUSION: The TIS regimen of AOM 400 mg demonstrated rapid symptomatic and functional improvement with good tolerability. Further large-scale prospective studies are warranted.
METHODS: This retrospective study included 50 patients diagnosed with schizophrenia according to DSM-5 criteria who received the TIS regimen of AOM 400 mg. Patients were divided into two groups: those followed with AOM monotherapy (Group 1) and those receiving AOM with oral agents (Group 2). Assessments included the Positive and Negative Syndrome Scale (PANSS), Clinical Global Impression scales (CGI-S, CGI-I, CGI-SE), and the Global Assessment of Functioning (GAF). Evaluations were performed at baseline and at weeks 1, 2, and 4. Hospital stay duration and side effects were recorded.
RESULTS: Both groups showed significant reductions in hospital stay and PANSS scores, with improved GAF and CGI-I scores (p < 0.001). No serious side effects occurred, and mild effects resolved by week 4.
CONCLUSION: The TIS regimen of AOM 400 mg demonstrated rapid symptomatic and functional improvement with good tolerability. Further large-scale prospective studies are warranted.